medigraphic.com

2017, Number 3

<< Back Next >>

Enf Infec Microbiol 2017; 37 (3)

Mortality associated with HIV-AIDS at the Tijuana General Hospital. Retrospective observational study

Navarro ÁS, Hurtado MJA, Falomir AA

Language: Spanish
References: 18
Page: 82-86
PDF size: 238.37 Kb.


ABSTRACT

In developed countries, the mortality of HIV-AIDS has declined dramatically and the causes of death increasingly resemble those of the general population. In Mexico, there is a decline, but the basic causes of death are unknown.
Material and Methods. A retrospective study was carried out, including cases of HIV infection and death, treated at the General Hospital Tijuana from January to November 2013.
Results. 84 deaths were documented, 68% were males and the mean age was 38.7 ± 11 years, the mean time of the HIV diagnosis was 5.5 days, 10% reported previous care at an AIDS clinic, and only 8% received antiretroviral therapy. The leading causes of death were non-AIDS-associated infections (44%) such as pneumonia, meningitis and tuberculosis, and AIDS complications (38%).
Discussion. The causes of death remain infectious complications and aids per se, due to late diagnosis and treatment, of disease.


REFERENCES

  1. “Pneumocystis carinii, Pneumocystis Pneumonia”, Morb Mortal Wkly Rep, 1996, 45 (34), 729-733. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00043494.htm.

  2. Centers for Disease Control (cdc), “Pneuocystis pneumonia”, Morb Mortal Wkly Rep, 1981, 30: 250-252.

  3. Nahmias, A.J., Weiss, J., Yao, X., Lee, F., Kodsi, R., Schanfield, M., Matthews, T., Bolognesi, D., Durack, D. y Motulsky, A., “Evidence for human infection with an htlv iii/lav-like virus in Central Africa, 1959”, Lancet, 1986, 1: 1279-1280, doi: 10.1016/S0140-6736 (86) 91422-91424.

  4. Unaids, julio de 2014, Epi Slides. Disponible en: http:// www.unaids.org/en/media/unaids/contentassets/documents/ document/2014/2014gapreportslides/01_Epi_slides_ 2014July.pdf.

  5. Lewden, Ch., May, T., Rosenthal, E., Burty, Ch., Bonnet, F., Costagliola, D., Jougla, E., Semaille, C., Morlat, P., Salmon, D., Cacoub, P. y Chêne, G., “Changes in causes of death among adults infected by hiv between 2000 and 2005: the ‘Mortalité 2000 and 2005’ Surveys”, hiv Med, 2005, 5: 99-106.

  6. Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., Myers, M.W. et al., “Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 cd4-positive cells per cubic millimeter”, N Engl J Med, 1990, 322: 941-949.

  7. Saravolatz, L.D., Winslow, D.L., Collins, G., James, D., Hodges, S., Petinelli, C., Stein, D.S., Markowitz, N., Reves, R., Loveless, M.O., Crane, L., Thompson, M. y Abrams, D., “Zidovudina alone or in combination with didanosine or zalcitabine in hiv-infected patients with the acquired immunodeficiency syndrome of fewer tan 200 cd4 cells per cubil millimeter”, N Engl J Med, 1996, 15 (335): 1081-1090.

  8. Palella, F.J. Jr., Delaney, K.M., Morrman, A.C., Loveless, M.O. et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection”, N Engl J Med, 1998, 13 (338): 853-860.

  9. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., D’Arminio Monforte, A., Knysz, B., Dietrich, M., Phillips, A.N. y Lundgren, J.D., “Eurosida study group. Decline in the aids and death rates in the Eurosida study: an observational study”, Lancet, 2003, 362 (9377): 22.

  10. Justice, A.C., “hiv and aging: time for a new paradigm”, cd4, Curr vih/aids Rep, 2010, 7: 69-76.

  11. Weber, R., Ruppik, M., Rickenbach, M., Spoerri, A., Furrer, H., Battegay, M., Cavassini, M., Calmy, A., Bernasconi, E., Schmid, P., Flepp, M., Kowalska, J. y Ledergerber, B., “Swiss hiv Cohort Study (shcs). Decreasing mortality and changing patterns of causes of death in the Swiss hiv Cohort Study”, hiv Med., 2013, 14 (4): 195-207.

  12. Brooks, J.T., Kaplan, J.E., Holmes, K.K., Benson, C., Pau, A. y Masur, H., “hiv-associated opportunistic infections, going, going, but not gone: the continued need for prevention and treatment guidelines”, Clin Infect Dis, 2009, 48 (5): 609-611.

  13. Goederta, J.J. y Bowerb, M., Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection”, Br J Cancer, 2010, 103 (3): 416-422.

  14. Smith C.,W.R., “dad Study Group. Trends over time in underlying causes of death in the dad study from 1999 to 2011”, xix International aids Conference, 22-27 de Julio de 2012, Washington, Abstract thab0304. Disponible en: http://www.clinicaloptions.com/HIV/Conference%20 Coverage/AIDS%202012/Highlights%20From%20 AIDS%202012/Capsules/THAB0304.aspx.

  15. Informe Censida. Disponible en: http://www.censida. salud.gob.mx/descargas/atencion/ Censidainforma.pdf.

  16. Sistema de Administración, Logística y Vigilancia de Antirretrovirales, Informe personalizado agosto de 2014.

  17. López Acle Delgado, A. “La deportación de mexicanos desde Estados Unidos: acción gubernamental y social en Tijuana, Baja California”, tesis de maestría en desarrollo social, Tijuana, B.C., 2012. Disponible en: http:// www.colef.mx/posgrado/wp-content/uploads/2014/03/ Tesis-completa-López-Acle-Delgado-Adriana.pdf.

  18. Brouwer, K.C., Lozada, R., Cornelius, W.A., Firestone Cruz, M., Magis-Rodríguez, C., Zúñiga de Nuncio, M.L. y Strathdee, S.A., “Deportation along the U.S.-Mexico Border: its relation to drug use patterns and accessing care”, J Immigr Minor Health, 2009, 11 (1): 1-6.




2020     |     www.medigraphic.com